<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> (CCH), featuring in most of the <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> spectrum, plays a detrimental role in brain amyloid-β (Aβ) homeostasis, cerebrovascular morbidity, and <z:hpo ids='HP_0001268'>cognitive decline</z:hpo>; therefore, early management of cerebrovascular pathology is considered to be important for intervention in the impending <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="50091">S-nitrosoglutathione</z:chebi> (<z:chebi fb="0" ids="50091">GSNO</z:chebi>) is an endogenous nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> carrier modulating endothelial function, <z:mp ids='MP_0001845'>inflammation</z:mp>, and neurotransmission </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, the effect of <z:chebi fb="0" ids="50091">GSNO</z:chebi> treatment on CCH-associated neurocognitive pathologies was determined in vivo by using rats with permanent bilateral common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> (BCCAO), a rat model of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We observed that rats subjected to permanent BCCAO showed a significant decrease in learning/memory performance and increases in brain levels of Aβ and vascular inflammatory markers </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="50091">GSNO</z:chebi> treatment (50 μg/kg/day for 2 months) significantly improved learning and memory performance of BCCAO rats and reduced the Aβ levels and ICAM-1/VCAM-1 expression in the brain </plain></SENT>
<SENT sid="5" pm="."><plain>Further, in in vitro cell culture studies, <z:chebi fb="0" ids="50091">GSNO</z:chebi> treatment also decreased the cytokine-induced proinflammatory responses, such as activations of NFκB and STAT3 and expression of ICAM-1 and VCAM-1 in endothelial cells </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, <z:chebi fb="0" ids="50091">GSNO</z:chebi> treatment increased the endothelial and microglial Aβ uptake </plain></SENT>
<SENT sid="7" pm="."><plain>Additionally, <z:chebi fb="0" ids="50091">GSNO</z:chebi> treatment inhibited the β-secretase activity in primary rat neuron cell culture, thus reducing secretion of Aβ, suggesting <z:chebi fb="0" ids="50091">GSNO</z:chebi> mediated mechanisms in anti-inflammatory and anti-amyloidogenic activities </plain></SENT>
<SENT sid="8" pm="."><plain>Taken together, these data document that systemic <z:chebi fb="0" ids="50091">GSNO</z:chebi> treatment is beneficial for improvement of <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> under the conditions of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> and suggests a potential therapeutic use of <z:chebi fb="0" ids="50091">GSNO</z:chebi> for <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> associated mild <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> in <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> </plain></SENT>
</text></document>